BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34948012)

  • 1. A Conserved Allosteric Site on Drug-Metabolizing CYPs: A Systematic Computational Assessment.
    Fischer A; Smieško M
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational diversity and ligand tunnels of mammalian cytochrome P450s.
    Yu X; Cojocaru V; Wade RC
    Biotechnol Appl Biochem; 2013; 60(1):134-45. PubMed ID: 23587001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying cytochrome p450 functional networks and their allosteric regulatory elements.
    Liu J; Tawa GJ; Wallqvist A
    PLoS One; 2013; 8(12):e81980. PubMed ID: 24312617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
    Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
    Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flexibility of human cytochrome P450 enzymes: molecular dynamics and spectroscopy reveal important function-related variations.
    Hendrychová T; Anzenbacherová E; Hudeček J; Skopalík J; Lange R; Hildebrandt P; Otyepka M; Anzenbacher P
    Biochim Biophys Acta; 2011 Jan; 1814(1):58-68. PubMed ID: 20656072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Dynamics Simulations Reveal Structural Differences among Allelic Variants of Membrane-Anchored Cytochrome P450 2D6.
    Fischer A; Don CG; Smieško M
    J Chem Inf Model; 2018 Sep; 58(9):1962-1975. PubMed ID: 30126275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes.
    Lewis DF
    Arch Biochem Biophys; 2003 Jan; 409(1):32-44. PubMed ID: 12464242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure conservation in cytochromes P450.
    Mestres J
    Proteins; 2005 Feb; 58(3):596-609. PubMed ID: 15617063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure.
    Lewis DF
    Xenobiotica; 2002 Apr; 32(4):305-23. PubMed ID: 12028664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation of cytochrome P450 isoenzyme activity in sheep liver and placental microsomes.
    Meakin AS; Amirmostofian M; Darby JR; Holman SL; Morrison JL; Wiese MD
    Placenta; 2023 Jan; 131():82-89. PubMed ID: 36527743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions.
    Maréchal JD; Kemp CA; Roberts GC; Paine MJ; Wolf CR; Sutcliffe MJ
    Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S82-9. PubMed ID: 18026129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of enzyme-ligand interactions in CYP2D6 & 3A4 homology models and crystal structures using a novel computational approach.
    Kjellander B; Masimirembwa CM; Zamora I
    J Chem Inf Model; 2007; 47(3):1234-47. PubMed ID: 17381082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 structure-function: insights from molecular dynamics simulations.
    Nair PC; McKinnon RA; Miners JO
    Drug Metab Rev; 2016 Aug; 48(3):434-52. PubMed ID: 27167388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substrate-Dependent Allosteric Regulation in Cytochrome P450cam (CYP101A1).
    Follmer AH; Mahomed M; Goodin DB; Poulos TL
    J Am Chem Soc; 2018 Nov; 140(47):16222-16228. PubMed ID: 30376314
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Lim SYM; Alshagga MA; Alshawsh MA; Ong CE; Pan Y
    Drug Metab Pers Ther; 2021 Aug; 37(1):55-67. PubMed ID: 35146975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How do substrates enter and products exit the buried active site of cytochrome P450cam? 1. Random expulsion molecular dynamics investigation of ligand access channels and mechanisms.
    Lüdemann SK; Lounnas V; Wade RC
    J Mol Biol; 2000 Nov; 303(5):797-811. PubMed ID: 11061976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome P450-The Wonderful Nanomachine Revealed through Dynamic Simulations of the Catalytic Cycle.
    Dubey KD; Shaik S
    Acc Chem Res; 2019 Feb; 52(2):389-399. PubMed ID: 30633519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ferrous and ferric state of cytochromes P450 in intact Escherichia coli cells: a possible role of cytochrome P450-flavodoxin interactions.
    Culka M; Milichovsky J; Jerabek P; Stiborova M; Martinek V
    Neuro Endocrinol Lett; 2015; 36 Suppl 1():29-37. PubMed ID: 26757119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D Spheroid Primary Human Hepatocytes for Prediction of Cytochrome P450 and Drug Transporter Induction.
    Järvinen E; Hammer HS; Pötz O; Ingelman-Sundberg M; Stage TB
    Clin Pharmacol Ther; 2023 Jun; 113(6):1284-1294. PubMed ID: 36906857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How do substrates enter and products exit the buried active site of cytochrome P450cam? 2. Steered molecular dynamics and adiabatic mapping of substrate pathways.
    Lüdemann SK; Lounnas V; Wade RC
    J Mol Biol; 2000 Nov; 303(5):813-30. PubMed ID: 11061977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.